Table 1.
Participant Demographics and Baseline Characteristics (N = 23)
| Characteristic | Participants, No. (%)a |
|---|---|
| Age, median (IQR), y | 15 (12–16) |
| Female sex | 18 (78) |
| Race | |
| Black or African American | 12 (52) |
| White | 8 (35) |
| Asian | 3 (13) |
| Hispanic ethnicity | 6 (26) |
| Study site | |
| United States | 20 (87) |
| Thailand | 3 (13) |
| Plasma HIV-1 RNA, median (IQR), log10 copies/mL | 4.3 (3.9–4.6) |
| CD4+ cell count, median (IQR), cells/µL | 466 (297–771) |
| CD4+ proportion, median (IQR), % | 22 (1–39) |
| CDC HIV-1 classification | |
| Stage 1 | 6 (26) |
| Stage 2 | 5 (22) |
| Stage 3 | 12 (52) |
| Prior ART experience | |
| NRTI | 23 (100) |
| PI | 18 (78) |
| NNRTI | 12 (52) |
| Triple class | 8 (35) |
| Enfuvirtide | 2 (9) |
| Duration of prior ART, median (IQR), y | 12.5 (10.8–14.0) |
Abbreviations: ART, antiretroviral therapy; CDC, US Centers for Disease Control and Prevention; HIV-1, human immunodeficiency virus type 1; IQR, interquartile range; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
aData represent No. (%) of participants unless otherwise specified.